Literature DB >> 2157858

The amino terminus of polyomavirus middle T antigen is required for transformation.

D N Cook1, J A Hassell.   

Abstract

In polyomavirus-transformed cells, pp60c-src is activated by association with polyomavirus middle T antigen. These complexes have a higher tyrosine kinase activity compared with that of unassociated pp60c-src. Genetic analyses have revealed that the carboxy-terminal 15 amino acids of pp60c-src and the amino-terminal half of middle T antigen are required for this association and consequent activation of the tyrosine kinase. To define in greater detail the borders of the domain in middle T antigen required for activation of pp60c-src, we constructed a set of unidirectional amino-terminal deletion mutants of middle T antigen. Analysis of these mutants revealed that the first six amino acids of middle T antigen are required for it to activate the kinase activity of pp60c-src and to transform Rat-1 fibroblasts. Analysis of a series of insertion and substitution mutants confirmed these observations and further revealed that mutations affecting the first four amino acids of middle T antigen reduced or abolished its capacity to activate the kinase activity of pp60c-src and to transform Rat-1 cells in culture. Our results suggest that the first four amino acids of middle T antigen constitute part of a domain required for activation of the pp60c-src tyrosyl kinase activity and for consequent cellular transformation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157858      PMCID: PMC249341          DOI: 10.1128/JVI.64.5.1879-1887.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Construction and expression of a recombinant DNA gene encoding a polyomavirus middle-size tumor antigen with the carboxyl terminus of the vesicular stomatitis virus glycoprotein G.

Authors:  D Templeton; A Voronova; W Eckhart
Journal:  Mol Cell Biol       Date:  1984-02       Impact factor: 4.272

2.  Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

3.  Polyoma virus middle T gene can trigger malignant transformation of early passage rodent cells.

Authors:  D A Spandidos; M Riggio
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

4.  Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin in vivo.

Authors:  M Kozak
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

5.  Deletions of N-terminal sequences of polyoma virus T-antigens reduce but do not abolish transformation of rat fibroblasts.

Authors:  M Katinka; M Yaniv
Journal:  Mol Cell Biol       Date:  1982-10       Impact factor: 4.272

6.  Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.

Authors:  M Kozak
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

7.  Transforming activity of polyoma virus middle-T antigen probed by site-directed mutagenesis.

Authors:  B A Oostra; R Harvey; B K Ely; A F Markham; A E Smith
Journal:  Nature       Date:  1983 Aug 4-10       Impact factor: 49.962

8.  Polyoma virus transforming protein associates with the product of the c-src cellular gene.

Authors:  S A Courtneidge; A E Smith
Journal:  Nature       Date:  1983 Jun 2-8       Impact factor: 49.962

9.  Mutations around the NG59 lesion indicate an active association of polyoma virus middle-T antigen with pp60c-src is required for cell transformation.

Authors:  S H Cheng; W Markland; A F Markham; A E Smith
Journal:  EMBO J       Date:  1986-02       Impact factor: 11.598

10.  Activation of the pp60c-src kinase by middle T antigen binding or by dephosphorylation.

Authors:  S A Courtneidge
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

View more
  11 in total

1.  The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.

Authors:  M Shanzer; I Ricardo-Lax; R Keshet; N Reuven; Y Shaul
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

2.  Functional asymmetry of the regions juxtaposed to the membrane-binding sequence of polyomavirus middle T antigen.

Authors:  J Dahl; U Thathamangalam; R Freund; T L Benjamin
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

3.  Genetic analysis of the polyomavirus DnaJ domain.

Authors:  Kerry A Whalen; Rowena de Jesus; Jennifer A Kean; Brian S Schaffhausen
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

5.  Tiny T antigen: an autonomous polyomavirus T antigen amino-terminal domain.

Authors:  M I Riley; W Yoo; N Y Mda; W R Folk
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Catalytically inactive protein phosphatase 2A can bind to polyomavirus middle tumor antigen and support complex formation with pp60(c-src).

Authors:  E Ogris; I Mudrak; E Mak; D Gibson; D C Pallas
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Identification of TAZ as a binding partner of the polyomavirus T antigens.

Authors:  Yu Tian; Dawei Li; Jean Dahl; John You; Thomas Benjamin
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 8.  T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis.

Authors:  Christopher S Sullivan; James M Pipas
Journal:  Microbiol Mol Biol Rev       Date:  2002-06       Impact factor: 11.056

9.  Amino-terminal regions of polyomavirus middle T antigen are required for interactions with protein phosphatase 2A.

Authors:  G M Glenn; W Eckhart
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.

Authors:  C T Guy; R D Cardiff; W J Muller
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.